GE HealthCare buying radiopharmaceutical firm Sofie Biosciences for $945M

GE HealthCare is acquiring Sofie Biosciences for $945M to obtain 15 radiopharma sites with 21 cyclotrons, bolstering its PET imaging and theranostics network, including FAPI-74, a phase 3 tracer.

• The deal grants GE HealthCare U.S. rights to FAPI-74, a phase 3 PET radiotracer with potential across multiple cancer types.
• Sofie currently manufactures Flyrcado (flurpiridaz F18 injection) for coronary artery disease detection; the acquisition expands GE’s footprint in the time-critical ‘final mile’ of PET dose distribution.
• The transaction is expected to close by July 2027, subject to government approval.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.